Houston-based NanoTech Inc. has announced it's closed its seed round of funding. Photo courtesy of NanoTech

It's payday for a Houston startup that is housed out of the new Halliburton Labs. Nanotech Inc., which material science for fire-proofing and insulation, has announced the close of its $5 million seed round.

According to NanoTech's news release, Austin-based Ecliptic Capital led the investment round. Additionally, the deal also resulted in the conversion of a simple agreement for future equity, or SAFE, that was previously issued to Halliburton Labs.

"The investment from Ecliptic Capital will allow us to scale our business to achieve our mission of fireproofing the world and reducing global energy consumption. Additionally, our participation with Halliburton Labs provides us with the support of a Fortune 500 company." says NanoTech's CEO Mike Francis in the release.

Based in Austin, Ecliptic Capital is a fund focused on early-stage startups and supports a wide range of technologies across neglected geographies and industries.

"Ecliptic is proud to partner with NanoTech as the company's founding institutional investor," says Mike W. Erwin, founder of Ecliptic Capital, in the release. "We're excited to work with the company and leverage our operational expertise to rapidly scale this impactful, world-changing technology. We look forward to a new world where NanoTech accelerates the thermal management market from science-fiction to science-fact."

Halliburton Company chose NanoTech among a round of contenders to be the first participant of their 12-month program located at their Houston headquarters. Halliburton provides Nanotech with its own office space, access to Halliburton facilities, technical expertise, and an extensive network to accelerate their product to market.

'We are thrilled to see a Halliburton Labs participant secure their first round of financing, and congratulate the Ecliptic and NanoTech teams,' says Scott Gale, Halliburton Labs executive director, in the release. 'We are confident in the path forward as they work towards achieving a clean energy future.'

NanoTech's proprietary technology has the ability to be utilized for various industries — including commercial construction, chemical plants, oil and gas, aviation, utilities and much more — for eco-friendly spray-on insulation and fireproofing.

"As a company, we are just scratching the surface on where our technology will be used and can't wait to see the business scale." adds Mike Francis.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

This Houston suburb named one of 10 newest boomtowns in U.S.

Booming 'Burb

What do you get when you combine a city's surge in population, housing growth, and economy? For the Houston suburb of Conroe, it adds up to being America's No. 9 newest boomtown, according to a new survey from SmartAsset.

The personal finance website's just-released report analyzed more than 400 U.S. cities with populations of 65,000 or more to identify places experiencing rapid growth based on five-year changes in economic output, housing units, and labor force size.

Texas is home to the second-highest concentration of new boomtowns in America with 18 out of 75 located in the Lone Star State. Only Florida ranks higher than Texas by just one.

However, Texas nearly locked out the top five most bustling boomtowns in America. Austin suburb Georgetown topped the list, and its Central Texas neighbors New Braunfels (No. 2) and Leander (No. 4) ranked close behind. Dallas-Fort Worth mid-city Lewisville claimed the No. 5 spot. Lehi, Utah ranked in third place.

Conroe has soared in popularity as one of America's most sought-after suburbs over the last several years, boosted by its renter-friendliness and its livability among the millennial generation.

Conroe has seen a 37 percent increase in housing units from 2019 to 2024, with its labor force growing by 33 percent during that time. SmartAsset also determined that Montgomery County's economic output grew at compound annual rates of 4.9 percent.

The report says population booms and "expanding business activity" can create "visible momentum" for an up-and-coming city, but these fast changes can alter a city in ways residents may not expect.

"In recent years, some American cities stand out for attracting people, investment and development at a pace that sets them apart," the report said. "Boomtown status does not mean growth benefits everyone equally, but it does reflect a city’s expanding economic capacity and the new opportunities that come with it."

America's top 10 new boomtowns are:

  • No. 1 – Georgetown
  • No. 2 – New Braunfels
  • No. 3 – Lehi, Utah
  • No. 4 – Leander
  • No. 5 – Lewisville
  • No. 6 – Palm Coast, Florida
  • No. 7 – Nampa, Idaho
  • No. 8 – McKinney
  • No. 9 – Conroe
  • No. 10 – Frisco
---

This article originally appeared on CultureMap.com.

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.